SNNAQ (Sienna Biopharmaceuticals) ROE % Adjusted to Book Value: -234.85% (As of Sep. 2019)


What is Sienna Biopharmaceuticals ROE % Adjusted to Book Value?

Sienna Biopharmaceuticals SNNAQ -99.00% ROE % Adjusted to Book Value is -234.85% as of Sep. 2019.

Sienna Biopharmaceuticals's ROE % for the quarter that ended in Sep. 2019 was -63.41%. Sienna Biopharmaceuticals's PB Ratio for the quarter that ended in Sep. 2019 was 0.27. Sienna Biopharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2019 was -234.85%.

Sienna Biopharmaceuticals ROE % Adjusted to Book Value Related Terms

Sienna Biopharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Sienna Biopharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sienna Biopharmaceuticals ROE % Adjusted to Book Value Chart

Sienna Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18
ROE % Adjusted to Book Value
0.00 0.00 -22.19 -68.55

Sienna Biopharmaceuticals Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.52 -118.85 -104.24 -111.93 -234.85

SNNAQ vs GTHR, PPCB, HSTC: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Sienna Biopharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sienna Biopharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sienna Biopharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Sienna Biopharmaceuticals's ROE % Adjusted to Book Value falls into.


Sienna Biopharmaceuticals ROE % Adjusted to Book Value Calculation

Sienna Biopharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2018 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-124.76% / 1.82
=-68.55%

Sienna Biopharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2019 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-63.41% / 0.27
=-234.85%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -234.85% mean?
Sienna Biopharmaceuticals (SNNAQ) has a ROE % Adjusted to Book Value of -234.85% as of Sep. 2019. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sienna Biopharmaceuticals and its competitors.
Is Sienna Biopharmaceuticals' ROE % Adjusted to Book Value too high?
Sienna Biopharmaceuticals' current ROE % Adjusted to Book Value is -234.85%.
How does Sienna Biopharmaceuticals' ROE % Adjusted to Book Value compare to GTHR and PPCB?
Sienna Biopharmaceuticals' ROE % Adjusted to Book Value of -234.85% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Sienna Biopharmaceuticals and its competitors. Sienna Biopharmaceuticals's current ROE % Adjusted to Book Value is -234.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sienna Biopharmaceuticals stock overvalued right now?
Sienna Biopharmaceuticals (SNNAQ) has a current ROE % Adjusted to Book Value of -234.85%. The current ROE % Adjusted to Book Value is -234.85%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Sienna Biopharmaceuticals (SNNAQ), the current ROE % Adjusted to Book Value is -234.85% as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sienna Biopharmaceuticals Business Description

Address 30699 Russell Ranch Road, Suite 140, Westlake Village, CA, USA, 91362
Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.